Business Context and Reporting Period
Company: Corcept Therapeutics Incorporated (CORT)
Filing Type: Form 8-K (Current Report)
Date of Report: October 10, 2025
Reporting Period: Event-based report regarding the termination of a material definitive agreement.
Key Financial Metrics
This filing does not contain financial statements, revenue, profit, cash flow, margin, debt, or liquidity data. The document is a current report focused on a contractual event rather than periodic financial performance.
Material Changes
- Termination of Distribution Agreement: On October 10, 2025, the Company delivered a notice to Optime Care, Inc. ("Optime") terminating the Distribution Services Agreement dated August 4, 2017 (as amended).
- Effective Date: The termination is effective as of January 8, 2026.
- Scope of Services: Optime served as the specialty pharmacy distributor for Korlym and the Company's authorized generic mifepristone, providing pharmacy operations, patient intake, reimbursement, support, claims management, and reporting.
- Background: The agreement was previously extended on April 1, 2024, through March 31, 2027, with automatic renewal options. On June 17, 2025, the Company notified Optime that it would cease to be the exclusive provider of these services effective September 15, 2025.
- Termination Rights: The Company exercised its right to terminate the agreement for convenience with 90 days' advance notice.
Guidance, Outlook, and Risks
Management Commentary: The filing confirms the Company's strategic decision to end its exclusive distribution relationship with Optime. The text does not provide specific forward-looking guidance on revenue impact or replacement distributor arrangements.
Risks and Contingencies: The agreement included customary termination provisions, including Optime's right to terminate in the event of a material breach by the Company that is not cured within a reasonable time. The filing notes that the description of the agreement is qualified by reference to the full agreement filed as Exhibit 10.2 to the Company's Form 10-Q for the quarter ended March 31, 2024.
Investor Verification Checklist
- Verify the Company's plan for transitioning pharmacy distribution services for Korlym and mifepristone after January 8, 2026.
- Review the full Distribution Services Agreement (Exhibit 10.2 to the Q1 2024 10-Q) to understand potential financial penalties or obligations associated with the termination.
- Monitor future filings for announcements regarding a new exclusive or non-exclusive distributor to replace Optime.
- Assess the potential impact on patient access and reimbursement processes during the transition period.